Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections

Clinical and Experimental Immunology

Volumn 186, Issue 2, 2016, Pages 249-265

  Hasan, A N ^a,b   Selvakumar, A ^b   Shabrova, E ^a   Liu, X R ^b   Afridi, F ^a   Heller, G ^c   Riviere, I ^d   Sadelain, M ^d   Dupont, B ^b   O'Reilly, R J ^a,b,d  

^a Division of Bone Marrow Transplantation   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d Center for Cell Engineering   (United States)

Author keywords

adoptive immunotherapy; cancer immunotherapy; cytokine; immune adjuvant; immunomodulation; T cell memory

Indexed keywords

B7 ANTIGEN; BETA 2 MICROGLOBULIN; HLA A ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ADOPTIVE IMMUNOTHERAPY; ANTI-INFECTIVE THERAPY; ANTIGEN PRESENTING CELL; APOPTOSIS ASSAY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MEMORY T LYMPHOCYTE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; STABLE EXPRESSION; T CELL CULTURE; TH1 CELL; TRANSIENT EXPRESSION;

EID: 84990245224     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12816     Document Type: Article

References (58)

1. Huang J, Khong HT, Dudley ME et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28:258–67.
2. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med 1995; 333:1038–44.
3. Wherry EJ, Teichgraber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225–34.
4. Quinn M, Turula H, Tandon M et al. Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. J Immunol 2015; 194:1726–36.
5. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294–305.
6. +) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014; 124:628–37.
7. Schluns KS, Lefrancois L. Cytokine control of memory T cell development and survival. Nat Rev Immunol 2003; 3:269–79.
8. Gerdemann U, Keirnan JM, Katari UL et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012; 20:1622–32.
9. + T cells for immunotherapy. Cancer Immunol Immunother 2011; 60:173–86.
10. + T cells in vivo by IL-15. Immunity 1998; 8:591–9.
11. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol 2001; 13:248–54.
12. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771–80.
13. Schluns KS, Williams K, Ma A et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827–31.
14. Imamura M, Shook D, Kamiya T et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 2014; 124:1081–8.
15. Roychowdhury S, May KF Jr, Tzou KS et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004; 64:8062–7.
16. Perna SK, De Angelis B, Pagliara D et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19:106–17.
17. Liu RB, Engels B, Schreiber K et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci USA 2013; 110:8158–63.
18. Dubois S, Mariner J, Waldmann TA et al. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537–47.
19. Chertova E, Bergamaschi C, Chertov O et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15.IL-15Ralpha cytokine compared to IL-15 monomer. J Biol Chem 2013; 288:18093–103.
20. Sato N, Patel HJ, Waldmann TA et al. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 2007; 104:588–93.
21. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072–80.
22. Xu W, Jones M, Liu B et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013; 73:3075–86.
23. + T cells. Cancer Res 2008; 68:2972–83.
24. Bergamaschi C, Rosati M, Jalah R et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008; 283:4189–99.
25. + T cells modifies adoptively transferred T cell function in cis. Eur J Immunol 2009; 39:491–506.
26. + T cell homeostasis. J Exp Med 2004; 200:825–34.
27. Mortier E, Woo T, Advincula R et al. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205:1213–25.
28. Hasan AN, Kollen WJ, Trivedi D et al. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol 2009; 183:2837–50.
29. Rodriguez-Tarduchy G, Collins M, Lopez-Rivas A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J 1990; 9:2997–3002.
30. Tamzalit F, Barbieux I, Plet A et al. IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci USA 2014; 111:8565–70.
31. + T cells. J Immunol 2008; 180:4391–401.
32. + lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644–56.
33. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2:551.
34. Koehne G, Hasan A, Doubrovina E et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 2015; 21:1663–78.
35. Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116:4360–7.
36. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676–80.
37. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101 Suppl 2:14639–45.]
38. + T cells against NY-ESO-1. N Engl J Med 2008; 358:2698–703.
39. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126–9.
40. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102:9571–6.
41. + T cells. J Clin Invest 2005; 115:1616–26.
42. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54–60.
43. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001; 14:105–10.
44. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29:848–62.
45. + bone marrow-derived cells. Blood 2004; 103:988–94.
46. + T cells in humans via recovering the phosphatidylinositol 3-kinase/AKT pathway. J Immunol 2007; 179:6734–40.
47. Traitanon O, Gorbachev A, Bechtel JJ et al. IL-15 induces alloreactive CD28(–) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation. Am J Transplant 2014; 14:1277–89.
48. + T cell subsets. Immunity 2009; 31:811–22.
49. Oh S, Hodge JW, Ahlers JD et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003; 170:2523–30.
50. Kerry SE, Buslepp J, Cramer LA et al. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol 2003; 171:4493–503.
51. Romano E, Cotari JW, Barreira da Silva R et al. Human Langerhans cells use an IL-15R-alpha/IL-15/pSTAT5-dependent mechanism to break T cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012; 119:5182–90.
52. Zhang M, Ju W, Yao Z et al. Augmented IL-15Ralpha expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol 2012; 188:6156–64.
53. Yu P, Steel JC, Zhang M et al. Simultaneous inhibition of two regulatory T cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA 2012; 109:6187–92.
54. Yu P, Steel JC, Zhang M et al. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16:6019–28.
55. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18:405–9.
56. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987; 196:947–50.
57. Koehne G, Smith KM, Ferguson TL et al. Quantitation, selection, and functional characterization of Epstein–Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002; 99:1730–40.
58. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99:1739–50.